NewsBenzingaRezolute Announces Results From Its Ongoing Open-Label Phase 3 upLIFT Study Of Ersodetug In Tumor Hyperinsulinism; Primary Efficacy Endpoint Has Been Achieved Based On Preliminary Results; Topline Results Expected By Mid-December 2026 Rezolute Announces Results From Its Ongoing Open-Label Phase 3 upLIFT Study Of Ersodetug In Tumor Hyperinsulinism; Primary Efficacy Endpoint Has Been Achieved Based On Preliminary Results; Topline Results Expected By Mid-December 2026 Benzinga 2026.11.13 11:20 (GMT+0) Open on Benzinga Other news Snowflake-Led AI Group Wins US Export Program Backing Solflare CEO: AI Security Reviews Being Built Into Development Pipeline, MoneyGram Integration Enables USDC-to-Cash Redemption Lighter Security Incident Update: About 5 Million USDC Returned to Affected Users, Withdrawals Resumed Supply Chain Attack on Optimizely Affects at Least 186 Websites, Aimed at Stealing Crypto Assets and Payment Info Jana Partners Cashes Out of One Data Center Stock for Another and Buys Trash Company Stock in Q3 Seth Klarman’s Baupost Group Takes New Position in Honeywell Aerospace in Q3
Solflare CEO: AI Security Reviews Being Built Into Development Pipeline, MoneyGram Integration Enables USDC-to-Cash Redemption
Lighter Security Incident Update: About 5 Million USDC Returned to Affected Users, Withdrawals Resumed
Supply Chain Attack on Optimizely Affects at Least 186 Websites, Aimed at Stealing Crypto Assets and Payment Info